The Pharmacological Management of Lennox-Gastaut Syndrome and Critical Literature Review

Lennox-Gastaut syndrome (LGS) is one of the most severe epileptic encephalopathies with childhood onset. It is characterized by the presence of (i) multiple, untreatable seizure types, including tonic seizures, atypical absences and tonic or atonic drop attacks, and (ii) electroencephalographic (EEG) abnormalities, consisting of interictal pattern of slow-spike waves (SSW) <3 Hz, and paroxysmal fast rhythms (10-20 Hz), mainly during non-REM sleep [1]. At the onset of the disorder, not all the different seizure types can be present [2].